Paolo Tarantino, MD, discusses how drug prices within the United States are affecting the treatment of breast cancer.

Watch Video

Remedying gaps in knowledge and implementing strategies for financial toxicity mitigation are important for optimizing breast cancer treatment.

View Article

Investigators identified a correlation between financial toxicity significant differences in mental and physical quality of life, and patient satisfaction with breast reconstruction among patients with breast cancer.

View Article

Patients have higher odds of experiencing rapid relapse in triple-negative breast cancer if they have Medicaid or no insurance, are single, are Black, and have not undergone surgery.

View Article

Research on NCCN resource-stratified guidelines for treating breast cancer could lead to overtreating patients in lower-middle and upper-middle income countries, while low-income populations could receive undertreatment.

View Article

The cost of treating and managing breast cancer will rise two-and-a-half times by 2030 due to expected increases in young women being diagnosed with metastatic disease.

View Article

A study led by Jefferson researchers found that not all patients, specifically African American patients and women without private insurance, receive the same breast cancer treatment, specifically the beneficial and more cost-effective hypofractionated whole breast radiation therapy.

View Article

Researchers indicated that especially among women considered to be midlife, metastatic breast cancer creates a high economic burden through lost productivity.

View Article